Obviousness-type double patenting is a serious consideration that patent owners should keep in mind during the examination of an application or in performing due diligence on a patent portfolio, says MaryAnne Armstrong.
The effect of obviousness-type double patenting on patent term extension and patent term adjustment in the biotech and pharma industry needs careful consideration, as Gaby L. Longsworth and Eric K. Steffe report.
The new examination guidelines do not carry the weight of law, and it is not likely that their more extreme aspects will withstand judicial scrutiny, but practitioners need to keep tabs on court decisions, says Courtenay C. Brinckerhoff.
With the Federal Circuit relying on the precedent set by the Prometheus and Myriad decisions, Dolly the sheep has been summarily declared ineligible for patent protection. Nabeela Rasheed sums up the implications.
With careful patent drafting and prosecution, it is possible to capture significant IP value in the clinically—and commercially—important area of biomarkers, says Stephanie Pilkington of Potter Clarkson.
Myriad has failed to stop Ambry offering genetic tests using the BRCA1 or BRCA2 genes, but Ambry raised a substantial question about the validity of the claims of Myriad’s patents, as MaryAnne Armstrong reports.
Apexigen uses antibodies derived from rabbits to develop therapies for diseases that are difficult to treat. LSIPR found out how it protects its novel technologies.
The US Supreme Court has again reversed a Federal Circuit decision, this time over burden of proof, says Matthew Nielsen.
In a global league, Canada’s biotech industry would be respectably mid table. LSIPR talks to Andrew Casey, president of industry association BIOTECanada, about how the organisation is trying to take it to the next level.
Stem cells are seen by many as the great hope for medical research in the years to come. LSIPR spoke to Nicholas Seay, chief technology officer at Cellular Dynamics, about the importance of IP in this field.